Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

48
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
48
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

62
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
62
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines of care for the management of atopic dermatitis in pediatric patients.

Journal of the American Academy of Dermatology·2026
Same author

Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis.

Journal of the American Academy of Dermatology·2026
Same author

Utilization and predictors of use of immunomodulators for atopic dermatitis: A cohort study.

JAAD international·2026
Same author

Topical steroid withdrawal syndrome: developing diagnostic criteria through a modified Delphi method.

The British journal of dermatology·2025
Same author

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

SAIGE I: Staphylococcus aureus, Immunological, Genetic, and Environmental (SAIGE) Factors Contributing to Atopic Dermatitis and the Use of Ceramide-Containing Skincare.

Journal of drugs in dermatology : JDD·2025

Related Experiment Video

Updated: Mar 30, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.8K

Systemic Agents for Severe Atopic Dermatitis in Children.

Eliza R Notaro1, Robert Sidbury2

  • 1Dermatology Division, Seattle Children's Hospital, University of Washington School of Medicine, 2480 Birch Ave N #1105, Seattle, WA, 98109, USA. elizas12@uw.edu.

Paediatric Drugs
|November 9, 2015
PubMed
Summary

Systemic therapies are crucial for severe atopic dermatitis (AD) when topical treatments fail. Early intervention with these treatments may prevent the progression of allergic diseases in children.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.3K

Related Experiment Videos

Last Updated: Mar 30, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.8K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.3K

Area of Science:

  • Dermatology
  • Immunology
  • Allergy

Background:

  • Atopic dermatitis (AD), or eczema, is a prevalent chronic inflammatory skin condition.
  • AD affects over 20% of the population in affluent countries, often presenting with relapsing pruritic, scaly, and erythematous lesions.
  • Superinfections are common in patients with atopic dermatitis.

Purpose of the Study:

  • To review the efficacy of systemic therapies for atopic dermatitis in children.
  • To discuss established non-specific immunosuppressive/immunomodulatory drugs and emerging targeted therapies.
  • To explore the potential prophylactic role of systemic therapy in preventing the atopic march.

Main Methods:

  • Review of existing literature on systemic treatments for atopic dermatitis.
  • Discussion of four established systemic non-specific immunosuppressive or immunomodulatory drugs: cyclosporine, mycophenolate mofetil, methotrexate, and azathioprine.
  • Overview of promising targeted therapies in development, such as dupilumab and apremilast, and other systemic interventions studied in pediatric AD.

Main Results:

  • Four systemic non-specific immunosuppressive or immunomodulatory drugs (cyclosporine, mycophenolate mofetil, methotrexate, azathioprine) have demonstrated efficacy in AD across age groups.
  • Systemic therapy is considered when topical treatments and phototherapy are insufficient or triggers are unavoidable.
  • Early aggressive systemic intervention may play a prophylactic role in preventing the atopic march.

Conclusions:

  • Systemic therapies are essential for managing severe, refractory atopic dermatitis.
  • Established systemic agents and novel targeted therapies offer effective treatment options for children with AD.
  • Further research into early intervention strategies is warranted to prevent the progression of allergic diseases.